PT2315834T - The tuberculosis rv2386c protein, compositions and uses thereof - Google Patents

The tuberculosis rv2386c protein, compositions and uses thereof

Info

Publication number
PT2315834T
PT2315834T PT97810576T PT09781057T PT2315834T PT 2315834 T PT2315834 T PT 2315834T PT 97810576 T PT97810576 T PT 97810576T PT 09781057 T PT09781057 T PT 09781057T PT 2315834 T PT2315834 T PT 2315834T
Authority
PT
Portugal
Prior art keywords
tuberculosis
compositions
rv2386c protein
rv2386c
protein
Prior art date
Application number
PT97810576T
Other languages
Portuguese (pt)
Inventor
Brown James
Mettens Pascal
Murphy Dennis
Original Assignee
Glaxosmithkline Biologicals Sa
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa, Glaxo Group Ltd filed Critical Glaxosmithkline Biologicals Sa
Publication of PT2315834T publication Critical patent/PT2315834T/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
PT97810576T 2008-07-25 2009-07-24 The tuberculosis rv2386c protein, compositions and uses thereof PT2315834T (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8369908P 2008-07-25 2008-07-25

Publications (1)

Publication Number Publication Date
PT2315834T true PT2315834T (en) 2018-08-10

Family

ID=41227131

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97810576T PT2315834T (en) 2008-07-25 2009-07-24 The tuberculosis rv2386c protein, compositions and uses thereof

Country Status (23)

Country Link
US (4) US20110206712A1 (en)
EP (1) EP2315834B1 (en)
JP (2) JP5981138B2 (en)
KR (1) KR20110049834A (en)
CN (2) CN106866801A (en)
AU (1) AU2009273132B2 (en)
BR (1) BRPI0916704A2 (en)
CA (1) CA2731547C (en)
CO (1) CO6351811A2 (en)
CY (1) CY1121632T1 (en)
DK (1) DK2315834T3 (en)
EA (1) EA201100070A1 (en)
ES (1) ES2685498T3 (en)
HR (1) HRP20181353T1 (en)
HU (1) HUE039159T2 (en)
IL (1) IL210589A (en)
LT (1) LT2315834T (en)
MX (1) MX2011000982A (en)
PL (1) PL2315834T3 (en)
PT (1) PT2315834T (en)
SI (1) SI2315834T1 (en)
UA (1) UA107329C2 (en)
WO (1) WO2010010179A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7842299B2 (en) * 2006-03-14 2010-11-30 Oregon Health & Science University Methods for producing an immune response to tuberculosis
US20110189217A1 (en) 2008-06-26 2011-08-04 Barry Michael A Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
PT2315834T (en) 2008-07-25 2018-08-10 Glaxosmithkline Biologicals Sa The tuberculosis rv2386c protein, compositions and uses thereof
BRPI0916705A2 (en) 2008-07-25 2015-11-10 Glaxo Group Ltd isolated polypeptide, isolated polynucleotide, pharmaceutical composition, immunogenic composition, method for treating or preventing tuberculosis, and uses of a polypeptide, and a polynucleotide.
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
WO2013090897A1 (en) * 2011-12-15 2013-06-20 The Trustees Of The University Of Pennsylvania Using adaptive immunity to detect drug resistance
CN104211787A (en) * 2013-05-31 2014-12-17 中国医学科学院病原生物学研究所 Protein for diagnosis and prevention of tuberculosis
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
JP6781698B2 (en) 2014-08-15 2020-11-04 オックスフォード イミュノテック リミテッド Mycobacterium tuberculosis protein
CN105572352B (en) * 2016-02-17 2017-07-28 遵义医学院附属医院 One group of tuberculosis latent infection diagnosis marker and application thereof
CN110035770B (en) 2016-12-07 2023-06-16 葛兰素史密丝克莱恩生物有限公司 New method
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
CN108950031A (en) * 2018-06-29 2018-12-07 周琳 The detection of rifampin resistant diagnosis marker of mycobacterium tuberculosis and its application
CN108866213A (en) * 2018-06-29 2018-11-23 周琳 Mycobacterium tuberculosis detection of rifampin resistant diagnosis marker and its application
CN109234414B (en) * 2018-06-29 2022-05-17 周琳 Diagnostic marker for resistance of mycobacterium tuberculosis to aminosalicylic acid and application of diagnostic marker
WO2020245207A1 (en) 2019-06-05 2020-12-10 Glaxosmithkline Biologicals Sa Saponin purification
KR20220032054A (en) * 2019-06-14 2022-03-15 스태튼스 세룸 인스티튜트 Fusion protein for tuberculosis vaccine
CN112457410B (en) * 2020-11-05 2023-04-07 迈克生物股份有限公司 Antigen composition for detecting mycobacterium tuberculosis infection
DE202022102137U1 (en) 2022-04-21 2022-04-28 Damayanthi Dalu A new composition for the treatment of tuberculosis
CN115073612B (en) * 2022-06-22 2024-09-27 宁夏大学 Mycobacterium tuberculosis Zera-71cA protein nanoparticle, preparation method and application thereof
CN115725607B (en) * 2022-07-14 2023-11-28 山东第一医科大学附属省立医院(山东省立医院) Pathogenic target gene of nocardia melitensis and application thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE188613T1 (en) 1992-06-25 2000-01-15 Smithkline Beecham Biolog VACCINE COMPOSITION CONTAINING ADJUVANTS
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
US7087713B2 (en) 2000-02-25 2006-08-08 Corixa Corporation Compounds and methods for diagnosis and immunotherapy of tuberculosis
US6613881B1 (en) 1997-05-20 2003-09-02 Corixa Corporation Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
JP4227302B2 (en) 1998-04-07 2009-02-18 コリクサ コーポレイション MYCOBACTERIUMUMBERBERCULOSIS antigen fusion protein and use thereof
JP5139618B2 (en) 2000-06-20 2013-02-06 コリクサ コーポレイション Mycobacterium tuberculosis fusion protein
US7538206B2 (en) 2001-02-22 2009-05-26 Institut Pasteur Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses
AU2003213118A1 (en) 2002-02-15 2003-09-09 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
US20030236393A1 (en) 2002-03-22 2003-12-25 United States Of America Dept Of Vetrans Affairs Virulence genes of M. marinum and M. tuberculosis
WO2005076010A2 (en) 2004-02-06 2005-08-18 Council Of Scientific And Industrial Research Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential
NZ562729A (en) * 2005-04-29 2009-10-30 Infectious Disease Res Inst Id Novel method for preventing or treating M tuberculosis infection using Mtb72f fusion proteins
WO2008007942A1 (en) 2006-07-10 2008-01-17 Het Nederlands Kanker Instituut Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof
CA2679410C (en) 2007-03-02 2017-01-17 Glaxosmithkline Biologicals S.A. Novel method and compositions
WO2010010178A1 (en) 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A The tuberculosis rv2707c protein, compositions and uses thereof
PT2315834T (en) * 2008-07-25 2018-08-10 Glaxosmithkline Biologicals Sa The tuberculosis rv2386c protein, compositions and uses thereof
BRPI0916705A2 (en) 2008-07-25 2015-11-10 Glaxo Group Ltd isolated polypeptide, isolated polynucleotide, pharmaceutical composition, immunogenic composition, method for treating or preventing tuberculosis, and uses of a polypeptide, and a polynucleotide.
BRPI0916703A2 (en) 2008-07-25 2019-12-24 Glaxo Group Ltd uses of a polypeptide, and a polynucleotide, and, composition
MX370744B (en) 2009-04-24 2019-12-20 A tuberculosis tb vaccine to prevent reactivation.
WO2010132112A2 (en) 2009-05-14 2010-11-18 Wisconsin Alumni Research Foundation Immunogenic compositions against tuberculosis
CN102869372B (en) 2010-01-27 2016-01-20 葛兰素史密丝克莱恩生物有限公司 Modified tuberculosis antigen

Also Published As

Publication number Publication date
EP2315834A1 (en) 2011-05-04
HUE039159T2 (en) 2018-12-28
US20110206712A1 (en) 2011-08-25
MX2011000982A (en) 2011-03-02
JP6104326B2 (en) 2017-03-29
JP2016000734A (en) 2016-01-07
US20170065697A1 (en) 2017-03-09
KR20110049834A (en) 2011-05-12
JP2011528896A (en) 2011-12-01
IL210589A0 (en) 2011-03-31
CY1121632T1 (en) 2020-07-31
BRPI0916704A2 (en) 2020-08-18
US9480735B2 (en) 2016-11-01
CN106866801A (en) 2017-06-20
ES2685498T3 (en) 2018-10-09
AU2009273132B2 (en) 2015-09-03
IL210589A (en) 2015-05-31
WO2010010179A1 (en) 2010-01-28
LT2315834T (en) 2018-09-10
UA107329C2 (en) 2014-12-25
CA2731547A1 (en) 2010-01-28
HRP20181353T1 (en) 2018-10-19
SI2315834T1 (en) 2018-09-28
EA201100070A1 (en) 2011-10-31
CN102165064B (en) 2017-06-20
JP5981138B2 (en) 2016-08-31
US10286053B2 (en) 2019-05-14
US20140314802A1 (en) 2014-10-23
DK2315834T3 (en) 2018-08-20
EP2315834B1 (en) 2018-06-13
CN102165064A (en) 2011-08-24
CA2731547C (en) 2019-04-30
CO6351811A2 (en) 2011-12-20
AU2009273132A1 (en) 2010-01-28
PL2315834T3 (en) 2018-12-31
US20140086948A1 (en) 2014-03-27

Similar Documents

Publication Publication Date Title
HRP20181353T1 (en) The tuberculosis rv2386c protein, compositions and uses thereof
IL250938A0 (en) Enzymatic fusion proteins, compositions comprising the same and uses thereof
HK1211040A1 (en) New albumin binding compositions, methods and uses
IL211762A0 (en) Pegylated opiods, compositions comprising the same and uses thereof
IL212836A0 (en) Azaquinolinone derivatives, compositions comprising the same and uses thereof
IL230759A0 (en) Substituted acylanilide, composition comprising it and uses thereof
IL220283A0 (en) 4-oxo-ih-quinoline-3- carboxamides, compositions comprising the same and uses thereof
EP2153838A4 (en) Anti-norovirus agent, and composition comprising the same
PL2271725T3 (en) Compositions comprising 2,3,3,3-tetrafluoropropene and 1,1,1-trifluoropropene
IL212278A0 (en) Morpholinopurine derivatives, compositions comprising the same and uses thereof
ZA201103584B (en) Whey protein compositions,methods and uses
IL211284A0 (en) Antibodies binding ccr2, compositions comprising the same and uses thereof
IL210722A0 (en) Benzazepine derivatives, compositions comprising the same and uses thereof
IL205705A0 (en) Anti-influenza antibodies, compositions comprising the same and uses thereof
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
IL213613A0 (en) Pyrazine derivatives, compositions comprising the same and uses thereof
GB0601143D0 (en) Uses, methods and compositions
IL206808A (en) Indolyl-pyridone derivatives, pharmaceutical compositions comprising the same and uses thereof
ZA201005278B (en) Folates, compositions and uses thereof
IL207372A0 (en) Phenylpyrrole derivatives, compositions comprising the same and uses thereof
GB0706077D0 (en) Methods, Compositions and uses thereof
IL205966A0 (en) Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof
IL213043A0 (en) Lantibiotic carboxyamide derivatives, compositions comprising the same and uses thereof
IL236601A0 (en) Antibody against cytomegalovirus, compositions comprising the same and uses thereof
IL207639A0 (en) Pyrrolopyrimidinecarboxamide compounds, compositions comprising the same and uses thereof